Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NKX2-5
REST API REST API
Homo sapiens
NKX2-5 is differentially expressed in 171 experiments: 68 organism parts: heart, spleen, ... (66 more);, 122 disease states: normal, acute lymphoblastic leukemia, ... (120 more);, 56 cell types 264 cell lines 24 compound treatments and 60 other conditions.
Synonyms CSX1, NKX2E, CSX, NKX2.5, NKX4-1
Orthologs F1NC42_CHICK (Gallus gallus)   Nkx2-5 (Mus musculus)   nkx2.5 (Danio rerio)   Q29RN9_BOVIN (Bos taurus)   F6VT63_CIOIN (Ciona intestinalis)   Nkx2-5 (Rattus norvegicus)   nkx2-5 (Xenopus laevis)   NP_001010959.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, cardiac muscle cell differentiation, regulation of transcription, DNA-dependent, cytoplasm, embryonic heart tube development, transcription, DNA-dependent, positive regulation of cell proliferation, positive regulation of gene expression, BMP signaling pathway, negative regulation of apoptosis, heart morphogenesis, positive regulation of heart contraction, cardiac muscle tissue development, transcription factor binding, cell differentiation, sequence-specific DNA binding, hemopoiesis, positive regulation of transcription from RNA polymerase II promoter, sarcomere organization, cardiac muscle contraction, multicellular organismal development, nucleus, heart development, protein heterodimerization activity, canonical Wnt receptor signaling pathway, transcription factor complex, positive regulation of transcription initiation from RNA polymerase II promoter, chromatin binding, protein homodimerization activity, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, cardiac ventricle morphogenesis, regulation of cardiac muscle cell proliferation, negative regulation of cardiac muscle cell apoptosis, outflow tract morphogenesis, atrial septum morphogenesis, pharyngeal system development, positive regulation of neuron differentiation, atrioventricular node cell development, serum response element binding, cardiac ventricle formation, outflow tract septum morphogenesis, proepicardium development, adult heart development, negative regulation of myotube differentiation, septum secundum development, pulmonary myocardium development, positive regulation of cardioblast differentiation, positive regulation of survival gene product expression, heart trabecula formation, cardiac muscle tissue morphogenesis, cardiac conduction system development, ventricular cardiac myofibril development, spleen development, vasculogenesis, atrioventricular node cell fate commitment, regulation of cardiac muscle contraction, atrial cardiac muscle cell development, cardiac Purkinje fiber cell differentiation, apoptosis involved in heart morphogenesis, ventricular septum morphogenesis, response to estradiol stimulus, positive regulation of calcium ion transport via voltage-gated calcium channel activity, ventricular trabecular myocardium morphogenesis, positive regulation of transcription via serum response element binding, thyroid gland development, bundle of His development, negative regulation of canonical Wnt receptor signaling pathway, atrioventricular node development, heart looping, embryonic heart tube left/right pattern formation, positive regulation of sodium ion transport, ventricular cardiac muscle cell development, sequence-specific DNA binding transcription factor activity, right ventricular cardiac muscle tissue morphogenesis, cardiovascular system development, transcription regulatory region DNA binding, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term Homeobox, Homeobox_eu
UniProt Accession A1ECB8, P52952, B4DNB6, E5RH49, E9PBU6
Gene-Disease Assocation TETRALOGY OF FALLOT, ATRIAL SEPTAL DEFECT WITH ATRIOVENTRICULAR CONDUCTION DEFECTS, HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5
Search EB-eye ENSG00000183072
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (15 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (26 experiments)

Factor Value U/D Experiments
HCC2157
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
SW480
2
E-MEXP-1014, E-MTAB-37
skmc myoblast
1
E-MTAB-62
NCIH1623
1
E-MTAB-37
MDAMB436
1
E-MTAB-62
258 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-11755, ... (29 experiments)

Factor Value U/D Experiments
epithelial cell
2
E-GEOD-4483, E-MEXP-2034
SCC
1
E-GEOD-19188
CD8+ T cell
1
E-MTAB-25
ADC
1
E-GEOD-19188
ovarian cancer
1
E-GEOD-21154
adult choroid from 76 y.o. donor
1
E-GEOD-18811
50 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-15960, E-MEXP-2069, E-GEOD-20602, ... (31 experiments)

Factor Value U/D Experiments
leiomyosarcoma
2
E-MTAB-37, E-MEXP-1922
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
renal clear cell carcinoma
1
E-MTAB-62
control
1
E-GEOD-20602
116 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-5741, E-GEOD-5824, E-GEOD-5099, ... (15 experiments)

Factor Value U/D Experiments
hydrogen peroxide
1
E-GEOD-5339
endotoxin
1
E-GEOD-3026
nocodazole
1
E-GEOD-571
saline
1
E-GEOD-3026
ox-LDL
1
E-GEOD-5741
control
31
1
E-GEOD-3284
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-MEXP-2340

Genotype
studied in E-GEOD-8167, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-1446, E-MEXP-1103 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, E-TABM-666, ... (22 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-43, E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.492 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM